Circulating tumour cells and cell-free DNA as tools for managing breast cancer (Q38109808)

29 August 2017

Circulating tumour cells and cell-free DNA as tools for managing breast cancer (English)

1 reference

29 August 2017

1 reference

Josep Tabernero Caturla

5

1 reference

29 August 2017

7

1 reference

29 August 2017

Leticia De Mattos-Arruda

1

object named as

Leticia De Mattos-Arruda

0 references

Jorge Reis-Filho

6

object named as

Jorge S Reis-Filho

1 reference

29 August 2017

Ana Vivancos

4

1 reference

ORCID Public Data File 2021

author name string

Leticia De Mattos-Arruda

1

1 reference

29 August 2017

Javier Cortes

2

1 reference

29 August 2017

Libero Santarpia

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

28 May 2013

1 reference

Nature Reviews Clinical Oncology

29 August 2017

1 reference

29 August 2017

10

1 reference

29 August 2017

377-389

1 reference

29 August 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2013.80

29 August 2017

0 references

cites work

Circulating tumor cells: liquid biopsy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Circulating tumor cells: approaches to isolation and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Gene expression profiling in breast cancer: classification, prognostication, and prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Challenges translating breast cancer gene signatures into the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Inferring tumor progression from genomic heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

CA 15-3: uses and limitation as a biomarker for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Serum tumor markers in breast cancer: are they of clinical value?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Molecular mechanisms of metastasis in breast cancer--clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Considerations in the development of circulating tumor cell technology for clinical use

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Molecular assays for the detection and characterization of CTCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Circulating tumour cells in non-metastatic breast cancer: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Meta-analysis of the prognostic value of circulating tumor cells in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Cell-free nucleic acids as biomarkers in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Detection of HER2 amplification in circulating free DNA in patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Genomic analysis of circulating cell-free DNA infers breast cancer dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Analysis of circulating tumor DNA to monitor metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Extracellular DNA in breast cancer: Cell-surface-bound, tumor-derived extracellular DNA in blood of patients with breast cancer and nonmalignant tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Prediction of breast tumor progression by integrity of free circulating DNA in serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Tumour evolution inferred by single-cell sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Development of personalized tumor biomarkers using massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

CTCs in primary breast cancer (I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Biomarkers characterization of circulating tumour cells in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

HER-2 gene amplification can be acquired as breast cancer progresses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

HER2-positive circulating tumor cells in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Advances in first-line treatment for patients with HER-2+ metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Treatment of HER2-positive breast cancer: current status and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

The implications of clonal genome evolution for cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Genome remodelling in a basal-like breast cancer metastasis and xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Biologic challenges in the detection of circulating tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

The landscape of cancer genes and mutational processes in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Abstract PD05-08: Genomic characterisation of invasive breast cancers with heterogeneous HER2 gene amplification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Genetic heterogeneity and cancer drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Whole-genome analysis informs breast cancer response to aromatase inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.80

Hormone receptor status, erbB2 expression and cancer stem cell characteristics of circulating tumor cells in breast cancer patients

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23712187

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23712187

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2013.80

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference